Sydney Stewart, Author at BioTuesdays

Developments

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

BeyondSpring (NASDAQ: BYSI) will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) annual meeting in...

March 25, 2019

Developments

Gritstone doses first patient in personalized immunotherapy trial

Gritstone Oncology (NASDAQ:GRTS) dosed the first patient with its personalized immunotherapy candidate targeting the patient’s tumor-specific neoantigens, called GRANITE-001. The Phase 1/2 clinical study is evaluating...

March 22, 2019

Executive Moves

BriaCell Therapeutics names two biopharma experts to its board

BriaCell Therapeutics (TSV-V:BCT; OTCQB:BCTXF) appointed Dr. Rebecca Taub and Vaughn Embro-Pantalony as directors, and current board members Dr. Saeid Babaei, Rahoul Sharan, and Martin Schmieg have resigned, effective...

March 18, 2019

Developments

Soleno Therapeutics Phase 3 trial for Prader-Willi Syndrome gets positive DSMB recommendation

Soleno Therapeutics (NASDAQ:SLNO) reported that the Data Safety Monitoring Board (DSMB) recommended continuation of the company’s Phase 3 trial in Prader-Willi Syndrome (PWS) patients, without any changes. The...

March 15, 2019

Developments

Akebia Therapeutics vadadustat meets primary endpoint in two Phase 3 trials

Akebia Therapeutics (NASDAQ:AKBA) vadadustat met its primary endpoint in two pivotal Phase 3 clinical trials for anemia due to chronic kidney disease (CKD). The trials compared the safety and efficacy of vadadustat to...

March 13, 2019

Developments

Neurocrine Biosciences reports positive Phase 2 congenital adrenal hyperplasia data

Neurocrine Biosciences (NASDAQ:NBIX) announced positive interim results from its Phase 2 proof-of-concept study evaluating NBI-74788 in adult patients with classic congenital adrenal hyperplasia (CAH). Classic CAH is a...

March 12, 2019

Developments

Seelos Therapeutics acquires exclusive license to Parkinson’s disease therapy

Seelos Therapeutics (NASDAQ:SEEL) acquired an exclusive license to a family of peptide inhibitors that target the aggregation of alpha-synuclein, a protein implicated in Parkinson’s disease (PD). Seelos will develop the...

March 8, 2019

Executive Moves

BioSig appoints Barry Keenan as VP of engineering

BioSig Technologies (NASDAQ:BSGM) named Barry Keenan as VP of engineering to head up the company’s advanced product development.

March 6, 2019

Markets

Analysts downgrade ImmunoGen after failed Phase 3 trial

Analysts at SVB Leerink and H.C. Wainwright downgraded Immunogen (NASDAQ:IMGN) and lowered their price targets after the company’s FORWARD-I Phase 3 trial with mirvetuximab soravtansine did not meet its primary endpoint...

March 4, 2019

Developments

Guardant Health liquid biopsy beats tissue testing in advanced non-small cell lung cancer

In a prospective multi-center study of 282 newly diagnosed non-small cell lung cancer patients, Guardant Health’s (NASDAQ:GH) liquid biopsy genomic assay, Guardant360, outperformed standard-of-care tissue testing in...

March 1, 2019

Author - Sydney Stewart

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

Gritstone doses first patient in personalized immunotherapy trial

BriaCell Therapeutics names two biopharma experts to its board

Soleno Therapeutics Phase 3 trial for Prader-Willi Syndrome gets positive DSMB recommendation

Akebia Therapeutics vadadustat meets primary endpoint in two Phase 3 trials

Neurocrine Biosciences reports positive Phase 2 congenital adrenal hyperplasia data

Seelos Therapeutics acquires exclusive license to Parkinson’s disease therapy

BioSig appoints Barry Keenan as VP of engineering

Analysts downgrade ImmunoGen after failed Phase 3 trial

Guardant Health liquid biopsy beats tissue testing in advanced non-small cell lung cancer

Subscribe